← Leaderboards
Jeffrey J. Ishizuka
Yale University
$3,062,580
Attributed
$3,062,580
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,062,580 · 3
By mechanism
K08$1,329,186 · 1
R37$1,263,556 · 1
R61$469,838 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Ruth Halaban$8,123,059
- Harriet M Kluger$18,066,555
- Carla Rothlin$8,894,958
- Robert E. Tigelaar$5,277,489
- Richard A Flavell$31,785,615
Others in their field
Other Emerging Leaders on “Genes”
- Leonard Freedman · Leidos Biomedical Research, Inc.$97,908,773
- Yunda Huang · Fred Hutchinson Cancer Center$51,342,169
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Lynn Briscoe · Leidos Biomedical Research, Inc.$41,311,588
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Evan Z Macosko · Broad Institute, Inc.$32,734,698
Research focus
GenesIn VivoTumor MicroenvironmentGeneticCytokineNeoplastic CellResponseTumorImmunotherapyInflammatoryProgramsMediatingComplexNovel Therapeutic InterventionNovel StrategiesRecruitInflammationAntibodiesInfiltrationInterferonsImmune Checkpoint BlockadeCellsMalignant NeoplasmsDouble-Stranded Rna
Grant awards (9)
Targeting dsRNA sensing and ADAR1 in melanoma$631,778
R37 · FY2025 · CA · contact PI
Multiplexed, Continuous Reporting of Gene Expression via CRISPR-mediated Transcriptional Activation$234,919
R61 · FY2025 · CA · contact PI
Targeting dsRNA sensing and ADAR1 in melanoma$631,778
R37 · FY2024 · CA · contact PI
Multiplexed, Continuous Reporting of Gene Expression via CRISPR-mediated Transcriptional Activation$234,919
R61 · FY2024 · CA · contact PI
Triggering Innate Immunity in Tumor Cells to Overcome Resistance to Immunotherapy$212,878
K08 · FY2024 · CA · contact PI
Triggering Innate Immunity in Tumor Cells to Overcome Resistance to Immunotherapy$279,077
K08 · FY2023 · CA · contact PI
Triggering Innate Immunity in Tumor Cells to Overcome Resistance to Immunotherapy$279,077
K08 · FY2022 · CA · contact PI
Triggering Innate Immunity in Tumor Cells to Overcome Resistance to Immunotherapy$279,077
K08 · FY2021 · CA · contact PI
Triggering Innate Immunity in Tumor Cells to Overcome Resistance to Immunotherapy$279,077
K08 · FY2020 · CA · contact PI